Can Mineralys Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 44.33 — current assets exceed current liabilities.

Where does Mineralys Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Mineralys Therapeutics, Inc. MLYS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$1.15M-14.6%	$1.03M+55.1%	$1.21M+142%	$1.01M+940%	$1.35M-74.9%
Restricted cash	$0—	$0—	$0—	$0—	$0—
Prepaid expenses and other current assets	$6.41M-44.2%	$4.75M-33.7%	$6.17M+49.4%	$10.35M+50.3%	$11.48M+39.1%
Total current assets	$652.47M+84.1%	$661.39M+222%	$599.8M+124%	$335.27M+5.4%	$354.51M+2.2%
Property and equipment, net	$32K-15.8%	$38K-28.3%	$7K-89.9%	$22K-47.6%	$38K-25.5%
Intangible assets, net	——	$1.82M-7.7%	——	——	——
Deferred tax assets	——	$55.1M+254%	——	——	——
Other non-current assets	$360K-9.3%	$382K-23.4%	$144K-68.1%	$433K-3.6%	$397K+4.7%
Held-to-maturity securities	——	$493.66M+333%	$480.48M+189%	$228.09M-6.2%	$217.77M-12.2%
Total assets	$652.86M+83.9%	$661.81M+221%	$599.95M+124%	$335.72M+5.4%	$354.94M+2.2%
Accounts payable	$1.12M+199%	$2.02M+321%	$1.12M-63.9%	$3.16M+85.4%	$373K-91.2%
Accrued expenses	$13.6M+4.5%	$13.1M-7.6%	$22.4M-20.6%	$19.01M-28.8%	$13.01M-12.9%
Accrued compensation	$2.31M+101%	$5.54M+54.7%	$3.88M+84.4%	$2.62M+96.6%	$1.15M+73.7%
Total current liabilities	$14.72M+10.0%	$15.11M+3.2%	$23.52M-24.9%	$22.17M-21.9%	$13.39M-30.3%
Common stock	500M0.0%	500M0.0%	500M0.0%	500M0.0%	500M0.0%
Additional paid-in capital	$1.13B+65.3%	$1.1B+124%	$1B+104%	$701.55M+44.0%	$686.28M+41.7%
Retained earnings	-$496.51M-44.0%	-$457.17M-51.1%	-$424.94M-67.6%	-$388M-96.7%	-$344.73M-121%
Total stockholders' equity	$638.14M+86.8%	$646.69M+238%	$576.43M+143%	$313.55M+8.1%	$341.56M+4.1%
Total liabilities and stockholders' equity	$652.86M+83.9%	$661.81M+221%	$599.95M+124%	$335.72M+5.4%	$354.94M+2.2%
Deferred Tax Assets and Other Non-Current Assets	$360K-9.3%	$3.22M+60.0%	$144K-68.1%	$433K-3.6%	$397K+4.7%
Deferred Tax Assets - Tax Credit Carryforwards	——	$21.6M+38.5%	——	——	——
Held-to-Maturity Debt Securities - Fair Value	——	$493.84M+333%	$480.51M+189%	$228.05M-6.2%	$217.75M-12.2%
Net Operating Loss Carryforwards	——	$59.5M+246%	——	——	——
Investments and Cash	$646.1M+88.4%	$656.6M+231%	$593.6M+125%	$324.9M+4.4%	$343M+1.3%
Other non-current assets	$360K-9.3%	$382K-23.4%	$144K-68.1%	$433K-3.6%	$397K+4.7%
Software and Technology Licenses, Net	$360K-9.3%	$382K-23.4%	$144K-68.1%	$433K-3.6%	$397K+4.7%
Tax Credit Carryforward Valuation Allowance	——	$121.25M+51.7%	——	——	——
Other Commercial Liabilities	$13.6M+4.5%	$13.1M-7.6%	$22.4M-20.6%	$19.01M-28.8%	$13.01M-12.9%
Accrued Liabilities, Current	$13.6M+4.5%	$13.1M-7.6%	$22.4M-20.6%	$19.01M-28.8%	$13.01M-12.9%
Professional Service Fees Payable	$6.7M+204%	$4.1M+108%	$3.88M+91.1%	$1.73M-16.8%	$2.2M+54.7%
Unrecognized Tax Benefits	——	$6.49M+44.0%	——	——	——
Unrecognized Tax Benefits - Income Tax Penalties and Interest Accrued	——	$0—	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	82.5M+27.1%	81.5M+63.7%	79M+58.7%	65.7M+32.2%	64.9M+30.7%
Common Stock Shares Outstanding	——	$146.32M+1,400%	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$8K+33.3%	$8K+60.0%	$8K+60.0%	$6K+20.0%	$6K+20.0%
Number of Exercisable Options	——	2M+60.4%	——	——	——
Number of Vested and Expected to Vest Options	——	$32.3M+669%	——	——	——
Share-Based Payment Award Options Outstanding - Number	7.4M+9.5%	6.6M+44.2%	6.6M+41.4%	7M+59.1%	6.8M+59.4%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	$48.7M+79.0%	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	14.1M+20.5%	10.4M+24.1%	10.8M+28.1%	11.6M+35.6%	11.7M+36.8%
Weighted Average Exercise Price of Outstanding Options	——	$14.40+22.4%	——	——	——
Professional service fees	$6.7M+204%	$4.1M+108%	$3.88M+91.1%	$1.73M-16.8%	$2.2M+54.7%
Research and development expenses	$4.59M-52.5%	$3.46M-59.8%	$14.64M-39.2%	$14.66M-37.0%	$9.66M-24.9%
Common stock, capital shares reserved for future issuance	$14.15M+20.5%	$10.42M+24.1%	$10.84M+28.1%	$11.57M+35.6%	$11.74M+36.8%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$500M0.0%	$500M0.0%	$500M0.0%	$500M0.0%	$500M0.0%
Common stock, shares issued (in shares)	$82.45M+27.1%	$81.54M+63.7%	$78.97M+58.7%	$65.73M+32.2%	$64.88M+30.7%
Common Stock, Shares, Outstanding	$82.45M+27.1%	$81.54M+63.7%	$78.97M+58.7%	$65.73M+32.2%	$64.88M+30.7%
Debt Securities, Current	$533.28M+200%	$483.71M+475%	$376.03M—	$223.13M—	$178.02M—
Deferred offering costs	$200K-33.3%	$200K-50.0%	$0-100%	$300K-25.0%	$300K0.0%
Capitalized research and development costs	——	$39.94M-11.2%	——	——	——
Deferred Tax Assets, Goodwill and Intangible Assets	——	$1.82M-7.7%	——	——	——
Deferred Tax Assets, Gross	——	$121.25M+51.7%	——	——	——
Deferred Tax Assets, Net of Valuation Allowance	——	$0—	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	$55.1M+254%	——	——	——
U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards	——	$244.6M+254%	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	——	$59.5M+246%	——	——	——
R&D credit carryforward	——	$21.17M+37.6%	——	——	——
Deferred Tax Assets, Valuation Allowance	——	$121.25M+51.7%	——	——	——
Cost not yet recognized	——	$48.7M+79.0%	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	$1.96M+60.4%	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$7.42M+9.5%	$6.58M+44.2%	$6.61M+41.4%	$6.99M+59.1%	$6.78M+59.4%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	——	$32.3M+669%	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	——	$14.4+22.4%	——	——	——
Fair value of options outstanding	——	$19.3M+117%	——	——	——
Incentive stock program, shares reserved for future grants (in shares)	$3.41M+8.6%	$2.04M-18.7%	$2.41M-1.5%	$2.76M-1.4%	$3.14M+5.3%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	$146.32M+1,400%	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	$12.31+27.7%	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	$46.98M+800%	——	——	——
Unrecognized tax benefits	——	$6.49M+44.0%	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Mineralys Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 44.33 — current assets exceed current liabilities.
Where does Mineralys Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.